Why Healthcare is (Finally) Chasing Consumers

Episode Summary

Executive Summary: The discussion examines healthcare’s 2018 volatility amid strong fundamentals, arguing that policy uncertainty—not operating weakness—is driving stock moves. It highlights consumerism, value-based care, vertical integration, Amazon’s potential role, data/AI, genomics, biotech financing, MedTech innovation, and China’s rising influence, while noting that drug-pricing politics and high valuations are tempering M&A.

Main Topics: Healthcare equities: strong fundamentals, macro and policy-driven volatility (Priority: 5/5): Joe argues that operating performance across healthcare remains strong, but sector stocks are pressured by broader market concerns and heightened policy uncertainty around inflation, interest rates, tax reform, and drug pricing. Sector winners and losers under policy risk (Priority: 5/5): Outperformance is concentrated in areas less exposed to pricing and reimbursement risk—med tech, life sciences tools, managed care, and hospitals—while pharma, PBMs, distributors, generics, and supply-chain businesses lag due to drug-pricing scrutiny. M&A is supported by cheap capital but constrained by valuation (Priority: 4/5): Despite abundant cash and low borrowing costs, deal activity is held back by all-time-high valuations and fear of overpaying. Many transactions are strategic rather than purely synergy-driven, and private equity can occasionally outbid strategics. Consumerism and value-based care are reshaping care delivery (Priority: 5/5): Rising deductibles and higher out-of-pocket costs are giving consumers more influence, pushing the system toward value-based care, lower-cost settings, and models that improve compliance and outcomes. Vertical integration and network control (Priority: 4/5): Insurers, pharmacy players, and integrated health companies are consolidating to control patient flow, manage chronic disease outcomes, and steer care toward lower-cost settings such as home care and palliative care. Technology, data, and genomics as long-term disruptors (Priority: 4/5): The conversation emphasizes the healthcare sector’s lag in IT/data infrastructure, the promise of patient-centric data systems and blockchain, and the early but rapid progress in genomics, gene therapy, and gene editing. China and new entrants such as Amazon (Priority: 3/5): China is moving up the healthcare technology curve, especially in oncology and gene editing, while Amazon is viewed as a credible consumer-facing force that could eventually influence chronic care and distribution models.

Key Arguments: Healthcare company operating performance is strong; stock weakness is mainly driven by macro and policy uncertainty rather than deteriorating fundamentals. Policy risk is uneven across the sector: med tech, research tools, managed care, and hospitals are less exposed, while pharma, PBMs, distributors, and generics face more pressure. M&A should be robust because companies have more cash and can borrow cheaply, but high valuations and concern about overpaying are slowing activity. Private equity can sometimes outbid strategics because low rates reduce financing costs, which is unusual in healthcare auctions. Consumer influence is rising because deductibles and out-of-pocket costs have increased, causing more delayed care and greater demand for cost control. Value-based care is no longer emerging—it is now embedded, with care shifting toward lower-cost settings and providers taking more risk on outcomes. Vertical consolidation is a rational response to uncertainty because controlling the provider, pharmacy, or care network helps manage chronic disease and patient behavior. Amazon’s most plausible impact is in consumer-facing chronic-care management and distribution, not necessarily in the most heavily regulated parts of reimbursement. Healthcare data remains fragmented, but connecting it could improve outcomes, especially by allowing treatment/outcome comparisons across populations and geographies. Genomics is still early-stage, but falling sequencing costs and advances in testing, gene therapy, and gene editing could transform disease treatment. Biotech companies can increasingly fund themselves through public markets, reducing dependence on M&A exits and private funding. Pharma is not cutting R&D; strong growth in CROs and research tools suggests spending remains healthy, but capital deployment is challenged by scarcity of large acquisition targets and pricing uncertainty. MedTech has matured past its earlier period of undifferentiated products and is now benefiting from value-based care, especially in areas like robotics and home-follow-up technology. China is becoming more important not just as a market but as an innovation source, especially in oncology and gene editing.

Data Points: Healthcare sector relative performance during policy uncertainty: 10% to 12% lower than the S&P on average - Referenced as historical proxy during major healthcare policy debates like Hillary Care/Obamacare Consumers with high-deductible insurance: 25% - Used to illustrate rising consumer cost exposure Average deductible: Over $2,000 - Current average cited as up from roughly $1,000 a decade earlier Average deductible a decade earlier: $1,000 - Shows how consumer out-of-pocket burden has risen over time Consumers delaying serious medical care: 25% - Evidence that high costs are causing patients to defer treatment Consumers delaying serious medical care in 2000: About 12% - Historical comparison for consumer behavior Employer insurance spend: Over $1 trillion - Context for the significance of employer-sponsored healthcare purchasing power Combined lives of Amazon, Berkshire Hathaway, and JPMorgan healthcare initiative: About 1 million - Described as the second-largest self-insured employer combination Largest self-insured employer benchmark: Walmart at about 1.3 million lives - Comparison point for the Amazon/Berkshire/JPMorgan initiative Patients accounting for majority of costs: Less than 10% of patients make up more than 50% of healthcare costs - Used to explain why chronic disease management is a major target Human genome sequencing cost in 2003: $100 million - Illustrates how expensive genomics used to be Human genome sequencing cost two years before the interview: $1,000 - Shows the dramatic decline in sequencing costs Projected genome sequencing cost soon after interview: $100 - Used to indicate how accessible genomics may become Global pharma M&A capacity (last year, with leverage): About $400 billion - Estimate of what major pharma could theoretically spend on acquisitions Biotech market cap above strategic acquisition threshold: A little over $300 billion - Compared with pharma’s potential buying power Global pharma cash deployable by 2020 post-tax reform: About $700 billion - Highlights expected surge in pharma cash generation Year of podcast recording: May 14, 2018 - Timestamp noted in the closing disclaimer

Pivotal Quotes: "The companies are still performing incredibly well. The margins, the growth profile, are probably the highest they've been in recent history." — Joe Natori: Explaining why healthcare stock weakness is likely macro- rather than operating-driven "Consumers are going to have more influence in healthcare." — Joe Natori: Summarizing the shift toward consumerism as deductibles rise and care costs are pushed to patients "The one thing that is certain is you need to consolidate influence." — Joe Natori: Describing why vertical integration and healthcare M&A are increasing

Implications: Expect continued healthcare policy sensitivity, more consumer-facing and vertically integrated models, and faster adoption of data/genomics tools. For investors, fundamentals remain sound, but valuation and regulation will keep dealmaking selective.